Skip to content

US · IDYA · BIOTECHNOLOGY

IDEAYA Biosciences, Inc. (IDYA) intrinsic value and stock valuation

$25.56as of 2026-11-21 · Mkt cap 3.52B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

IDEAYA Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values IDYA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from IDYA’s statements →

IDEAYA Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 ideayabio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$218.7M+62.1% 5y CAGRd
20172025
Net income
-$-113.7M
20172025
Free cash flow
-$-73.47M
20172025
Total equity
$1.02B+38.8% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$218.7M$7M$23.4M$50.9M$27.9M
Operating income-$-159.31M-$-326.98M-$-134.43M-$-62.5M-$-50.27M
Net income-$-113.7M-$-274.48M-$-112.96M-$-58.66M-$-49.76M
EPSd-$-1.28M-$-3.36M-$-1.96M-$-1.42M-$-1.41M
Operating cash flow-$-71.1M-$-247.58M-$-115.22M-$-87.17M-$-55.78M
Capital expenditure-$-2.37M-$-3.86M-$-2.37M-$-3.44M-$-2.64M
Free cash flow-$-73.47M-$-251.44M-$-117.59M-$-90.62M-$-58.42M
Total assets$1.11B$1.12B$649.3M$388M$381.4M
Total debt$27.9M$19.2M$2.87M$3.48M$5.18M
Net debt-$-84.91M-$-65.21M-$-154.15M-$-65.15M-$-86.86M
Total equity$1.02B$1.06B$621.1M$349.5M$301.5M
Cash and short-term investments$639.4M$676.3M$525.1M$364.8M$246.8M
Income statement
20252024202320222021
Revenue$218.7M$7M$23.4M$50.9M$27.9M
Cost of revenue$4.59M$3.83M$4.01M$2.1M$1.73M
Gross profit$214.1M$3.17M$19.4M$48.8M$26.2M
Research and development expenses$314.7M$294.7M$129.5M$89.5M$58.2M
Selling, general and administrative expenses$63.3M$35.5M$24.3M$21.8M$18.3M
Other expenses-$-4.59M$0.00$0.00$0.00$0.00
Operating expenses$373.4M$330.1M$153.8M$111.3M$76.5M
Cost and expenses$378M$334M$157.8M$113.4M$78.2M
Interest income$45.6M$52.5M$21.5M$3.85M$510K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$4.59M$3.83M$4.01M$2.1M$1.73M
Ebitda-$-109.11M-$-270.64M-$-108.95M-$-56.55M-$-48.04M
Operating income-$-159.31M-$-326.98M-$-134.43M-$-62.5M-$-50.27M
Total other income/expenses, net$45.6M$52.5M$21.5M$3.85M$510K
Income before tax-$-113.7M-$-274.48M-$-112.96M-$-58.66M-$-49.76M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-113.7M-$-274.48M-$-112.96M-$-58.66M-$-49.76M
Weighted average shares outstanding$88.5M$81.7M$57.5M$41.4M$35.3M
Weighted average diluted shares outstanding$88.5M$81.7M$57.5M$41.4M$35.3M
Balance sheet
20252024202320222021
Cash and short-term investments$639.4M$676.3M$525.1M$364.8M$246.8M
Net receivables$5.97M$0.00$20K$210K$1.1M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$666.7M$689.7M$532.6M$370.5M$251M
Property, plant and equipment, net$31.3M$27.7M$8.41M$8.99M$8.66M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$410.3M$405.8M$107.5M$8.32M$121.3M
Total non-current assets$442.6M$434.4M$116.7M$17.5M$130.4M
Total assets$1.11B$1.12B$649.3M$388M$381.4M
Accounts payable$17.6M$15.4M$6.6M$4.28M$2.1M
Short-term debt$340K$300K$1.75M$1.87M$1.7M
Deferred revenue$0.00$0.00$0.00$8.57M$29M
Total current liabilities$58.8M$46.1M$27.1M$31.7M$45.2M
Long-term debt$27.6M$18.9M$1.12M$1.61M$3.48M
Deferred revenue, non-current$0.00$0.00$0.00$5.18M$31.2M
Total non-current liabilities$27.6M$18.9M$1.12M$6.8M$34.7M
Capital lease obligations$0.00$19.2M$2.87M$3.48M$5.18M
Total liabilities$86.4M$64.9M$28.2M$38.5M$79.8M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-736.54M-$-622.84M-$-348.36M-$-235.4M-$-176.75M
Accumulated other comprehensive income (loss)$2.27M$810K$560K-$-2.87M-$-710K
Total equity$1.02B$1.06B$621.1M$349.5M$301.5M
Total investments$936.9M$997.8M$475.6M$304.5M$276M
Total debt$27.9M$19.2M$2.87M$3.48M$5.18M
Net debt-$-84.91M-$-65.21M-$-154.15M-$-65.15M-$-86.86M
Cash flow statement
20252024202320222021
Net income-$-113.7M-$-274.48M-$-112.96M-$-58.66M-$-49.76M
Depreciation and amortization$4.59M$3.83M$4.01M$2.1M$1.73M
Stock-based compensation$46.1M$34.8M$18.5M$11.6M$8.24M
Change in working capital$1.87M$11.6M-$-13.21M-$-41.55M-$-17.81M
Accounts receivable$0.00$10K$190K$890K$770K
Inventory$0.00$0.00$0.00$0.00$3.79M
Accounts payable$2.7M$8.28M$2.63M$1.86M$1.17M
Net cash provided by operating activities-$-71.1M-$-247.58M-$-115.22M-$-87.17M-$-55.78M
Investments in property, plant and equipment-$-2.37M-$-3.86M-$-2.37M-$-3.44M-$-2.64M
Acquisitions, net$0.00$0.00$0.00$33.4M$67M
Net cash used for investing activities$70M-$-502.56M-$-158.46M-$-33.4M-$-69.67M
Common stock issued$29.8M$654.2M$309.8M$95M$143.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$29.8M$677.6M$362.7M$97.2M$145.5M
Net change in cash$28.5M-$-72.59M$89M-$-23.41M$20M
Cash at end of period$112.8M$85.2M$157.8M$68.7M$92.2M
Operating cash flow-$-71.1M-$-247.58M-$-115.22M-$-87.17M-$-55.78M
Capital expenditure-$-2.37M-$-3.86M-$-2.37M-$-3.44M-$-2.64M
Free cash flow-$-73.47M-$-251.44M-$-117.59M-$-90.62M-$-58.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About IDEAYA Biosciences, Inc.

        IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.

        CEO
        Yujiro S. Hata
        Employees
        145
        Beta
        -0.09

        Explore

        Frequently asked questions

        What is the intrinsic value of IDEAYA Biosciences, Inc. (IDYA)?

        IDEAYA Biosciences, Inc. (IDYA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is IDYA undervalued?

        IDYA trades at a price of $25.56 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.